ENB-838

ENB-838 is a preclinical-stage precision oncology drug candidate being developed by Engine Biosciences for the treatment of various solid tumors, including ovarian, colorectal, and lung cancers. The compound was discovered using Engine's proprietary NetMAPPR AI platform and CombiGEM high-throughput biological experimentation system, which identify novel gene interactions and synthetic lethal vulnerabilities in cancer cells. As part of Engine's precision medicine strategy, ENB-838 is designed to be paired with specific biomarkers to identify patient populations most likely to benefit from the therapy. While the exact molecular target of ENB-838 has not been publicly disclosed, the program focuses on leveraging novel target-biomarker combinations to overcome resistance and improve treatment efficacy in difficult-to-treat cancers.